Shailesh Ayyangar, managing director of Sanofi India and president, Organisation of Pharmaceutical Producers of India (OPPI), tells Veena Mani that India needs to have set criteria to define “essentiality&" of medicines, for bringing these
The Drugs Controller General of India (DCGI) has again found Sanofi's popular painkiller drug, Combiflam, of 'sub-standard' quality, in its latest test last month. It had found the same defect in the medicine in February and April, too.
Sanofi Pasteur, the vaccine division of Sanofi, announced today that it has begun commercial manufacturing at the new vaccines' production facility of its affiliate Shantha Biotechnics Private Limited.
As the Drugs Controller General of India (DCGI) found Sanofi’s popular painkiller drug, Combiflam, to be of sub-standard quality twice in the past three months, the company has recalled the affected batches.
Shares of Sanofi India are up over 2% at Rs 4,331 on the BSE after Sanofi Pasteur, the vaccine division of drug maker Sanofi, has completed the first study of the effects of Dengvaxia, the world's first dengue vaccine approved in Mexico, on Indian adults
Shares of Sanofi India were up nearly 3% at Rs 3,620 after the company posted nearly 12% growth in net profit at Rs 64.20 crore for the quarter ended June 30, 2015 compared to Rs 57.50 crore for the same quarter last fiscal.
If Vijay Mallya faces allegations of financial irregularities and has been asked by the new owner, Diageo, to step down from United Spirits’ board, is it appropriate for other companies to have him on board?That is what proxy advisory firm
Sanofi Pasteur, the vaccine division of Sanofi, announced today that its affiliate Shantha Biotechnics has delivered the first 4 lakh doses of its pediatric Pentavalent vaccine Shan5 to support the immunisation of children in cities of Gwalior and
Punjab Deputy Chief Minister Sukhbir Singh Badal on Thursday said Punjab was all set to emerge as the pharmaceutical hub of the country, with foremost health sector players eying towards the state for their major investment plans in the Medicity at New
Sanofi India has gained 4%, extending its 11% rally in the previous session, as the company would benefit the most after the government withdrew National Pharmaceutical Pricing Authority's power that permitted it to fix prices of non-essential drugs.
Sanofi India has surged 12% to Rs 3,350 on National Stock Exchange after the government withdrew National Pharmaceutical Pricing Authority's power that permitted it to fix prices of non-essential drugs.
The Competition Commission has cleared pharmaceutical firm Sanofi-Synthelabo's proposed stake buy in an arm of Apollo group, saying the deal does not raise any concerns related to unfair business practices.
Drug firm Sanofi India today reported 44.22% decline in net profit at Rs 51.7 crore for the fourth quarter ended March 31, 2014.The company had posted a net profit of Rs 92.7 crore during the same period last year.